1076 related articles for article (PubMed ID: 17203887)
21. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian perspective.
Mizokami A; Ueno S; Fukagai T; Ito K; Ehara H; Kinbara H; Origasa H; Usami M; Namiki M; Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():6-9; discussion 17-8. PubMed ID: 17229160
[TBL] [Abstract][Full Text] [Related]
22. Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia.
Maluta S; Dall'oglio S; Nadalini L
Int J Hyperthermia; 2010; 26(8):765-74. PubMed ID: 21043571
[TBL] [Abstract][Full Text] [Related]
23. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
24. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
Anscher MS; Clough R; Robertson CN; Prosnitz LR; Dahm P; Walther P; Donatucci CF; Albala DM; Febbo P; George DJ; Sun L; Moul JW
Prostate Cancer Prostatic Dis; 2006; 9(3):254-60. PubMed ID: 16880828
[TBL] [Abstract][Full Text] [Related]
25. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Bolla M
Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
[TBL] [Abstract][Full Text] [Related]
27. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
Bolla M; Fourneret P; Descotes JL
Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
[TBL] [Abstract][Full Text] [Related]
28. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
Roach M
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
[TBL] [Abstract][Full Text] [Related]
29. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer.
Jereczek-Fossa BA; Orecchia R
Radiother Oncol; 2007 Aug; 84(2):197-215. PubMed ID: 17532494
[TBL] [Abstract][Full Text] [Related]
30. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
Bria E; Cuppone F; Giannarelli D; Milella M; Ruggeri EM; Sperduti I; Pinnarò P; Terzoli E; Cognetti F; Carlini P
Cancer; 2009 Aug; 115(15):3446-56. PubMed ID: 19484790
[TBL] [Abstract][Full Text] [Related]
31. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up after triple treatment of prostate cancer stage pT3.
Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
[TBL] [Abstract][Full Text] [Related]
34. [Basic principles and initial results of adjuvant hormone therapy and irradiation of prostatic carcinoma].
Dearnaley DP; Shearer RJ; Ellingham L; Gadd J; Horwich A
Praxis (Bern 1994); 1997 Nov; 86(48):1895-901. PubMed ID: 9480509
[TBL] [Abstract][Full Text] [Related]
35. Radiation therapy for high-risk prostate cancer--a review.
Skala M; Rosewall T; Warde P
Can J Urol; 2005 Jun; 12 Suppl 2():28-32. PubMed ID: 16018830
[TBL] [Abstract][Full Text] [Related]
36. [Adjuvant and salvage radiotherapy after radical prostatectomy].
Milecki P; Kwias Z; Skowronek J; Stachowski T
Pol Merkur Lekarski; 2004 May; 16(95):495-9. PubMed ID: 15518437
[TBL] [Abstract][Full Text] [Related]
37. Management of high-risk prostate cancer: radiation therapy and hormonal therapy.
Nomiya T; Tsuji H; Toyama S; Maruyama K; Nemoto K; Tsujii H; Kamada T
Cancer Treat Rev; 2013 Dec; 39(8):872-8. PubMed ID: 23648323
[TBL] [Abstract][Full Text] [Related]
38. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
39. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
40. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]